CoChat

Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells

Open access
Yi, Yong Weon, Kang, Hyo Jin, Kim, Hee Jeong, Kong, Yali, Brown, Milton L., Bae, Insoo · 2013 · Oncotarget
Cited by 94

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

// Yong Weon Yi 1,* , Hyo Jin Kang 1,* , Hee Jeong Kim 1 , Yali Kong 3 , Milton L. Brown 3 and Insoo Bae 1,2,3 1 Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 2 Department of Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 3 Center for Drug Discovery, Georgetown University, Washington, DC * These authors contributed equally Correspondence: Milton L. Brown, email: // Insoo Bae, email: // Keywords : mutant p53 (mtp53), deacetylation, SIRT1, activator, triple-negative breast cancer (TNBC) Received : May 31, 2013 Accepted : June 20, 2013 Published : July 5, 2013 Abstract Many types of mutations in tumor suppressor p53 are oncogenic through gain-of-function. Therefore, targeting mutant p53 (mtp53) is a promising therapeutic approach to fight against many types of cancers. We report here a small molecule compound YK-3-237 that reduces acetylation of mtp53 and exhibits anti-proliferative effects toward triple-negative breast cancer (TNBC) cells carrying mtp53. YK-3-237 activates SIRT1 enzyme activities in vitro and deacetylation of both mtp53 and wild type p53 (WTp53) in a SIRT1-dependent manner. Deacetylation of mtp53 resulted in depletion of mtp53 protein level and up-regulated the expression of WTp53-target genes, PUMA and NOXA. YK-3-237 also induces PARP-dependent apoptotic cell death and arrests the cell cycle at G2/M phase in mtp53 TNBC cells. Taken together, our data suggest that targeting acetylation of mtp53 is a potential target to treat human cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.1070

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 94

Metadata

Authors
Yi, Y. W., Kang, H. J., Kim, H. J., Kong, Y., Brown, M. L., & Bae, I.
Venue
Oncotarget
Published
2013-07-05
Volume
4
Issue
7
Pages
984-994
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1574146295
Cited by
94
References
17
FWCI
3.79
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells. https://app.cochat.ai/papers/10.18632/oncotarget.1070
The paper
Yi, Y. W., Kang, H. J., Kim, H. J., Kong, Y., Brown, M. L., & Bae, I. (2013). Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells. Oncotarget. https://doi.org/10.18632/oncotarget.1070

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.